We are live on ! Find out more
PTCT icon

PTC Therapeutics
PTCT

132 hedge funds and large institutions have $1.47B invested in PTC Therapeutics in 2014 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 58 increasing their positions, 23 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

660% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 5

152% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 23

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

37% more capital invested

Capital invested by funds: $1.07B → $1.47B (+$395M)

33% more funds holding

Funds holding: 99 → 132 (+33)

53% less call options, than puts

Call options by funds: $1.5M | Put options by funds: $3.18M

Holders
132
Holders Change
+33
Holders Change %
+33.33%
% of All Funds
3.52%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
38
Increased
58
Reduced
23
Closed
5
Calls
$1.5M
Puts
$3.18M
Net Calls
-$1.68M
Net Calls Change
-$1.68M

Top Buyers

Rank Fund Capital Flow
1
BB
BB Biotech
Switzerland
+$54.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$26.8M
3
CCI
Columbus Circle Investors
+$26.8M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$25.5M
5
CCM
Camber Capital Management
Massachusetts
+$16.1M

Top Sellers

Rank Fund Capital Flow
1
BCPEM
Bain Capital Public Equity Management
Massachusetts
-$34.3M
2
CS
Credit Suisse
Switzerland
-$16.7M
3
Millennium Management
Millennium Management
New York
-$14.1M
4
SAM
Sectoral Asset Management
Quebec, Canada
-$8.24M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$7.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
76
Price Capital Management
Louisiana
$1.31M +$1.11M +25,218 New
Swiss National Bank
77
Swiss National Bank
Switzerland
$1.2M +$144K +3,280 +17%
RhumbLine Advisers
78
RhumbLine Advisers
Massachusetts
$1.1M +$88K +2,000 +10%
Marshall Wace
79
Marshall Wace
United Kingdom
$1.08M +$580K +13,186 +173%
LI
80
LMCG Investments
Massachusetts
$1.07M +$909K +20,659 New
GH
81
GAM Holding
Switzerland
$1.05M – – –
BC
82
Birchview Capital
Vermont
$1.03M +$876K +19,900 New
Goldman Sachs
83
Goldman Sachs
New York
$1.01M -$567K -12,874 -40%
WPP
84
Whalerock Point Partners
Rhode Island
$995K +$104K +2,370 +14%
Morgan Stanley
85
Morgan Stanley
New York
$887K +$255K +5,791 +51%
CCM
86
Cadence Capital Management
Massachusetts
$845K +$718K +16,320 New
Susquehanna International Group
87
Susquehanna International Group
Pennsylvania
$817K +$695K +15,781 New
Citigroup
88
Citigroup
New York
$816K +$462K +10,492 +199%
AIG
89
American International Group
New York
$796K +$37.6K +854 +6%
FMT
90
First Mercantile Trust
Tennessee
$754K +$435K +9,890 +212%
1CM
91
1492 Capital Management
Wisconsin
$737K +$627K +14,243 New
State Board of Administration of Florida Retirement System
92
State Board of Administration of Florida Retirement System
Florida
$730K – – –
Connor, Clark & Lunn Investment Management (CC&L)
93
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$689K +$585K +13,300 New
VOYA Investment Management
94
VOYA Investment Management
Georgia
$671K – – –
PPA
95
Parametric Portfolio Associates
Washington
$614K +$39.8K +905 +8%
American Century Companies
96
American Century Companies
Missouri
$552K +$469K +10,662 New
DC
97
Deere & Company
Illinois
$539K – – –
SG Americas Securities
98
SG Americas Securities
New York
$537K +$457K +10,375 New
BOTOTLSJU
99
Board of Trustees of The Leland Stanford Junior University
California
$533K – – –
CAM
100
Cormorant Asset Management
Massachusetts
$518K -$5.06M -115,000 -92%
2 3
4
5 6

PTCT Hedge Fund Activity: Q4 2014 in Review

132 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2014, worth a combined $1.47B — up 37% from $1.07B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new PTCT positions and 5 closed out — a net gain of 33 holders — while 58 added to existing stakes and 23 trimmed.

The largest buyer was BB Biotech, opening a new position worth an estimated $54.1M. The largest seller was Bain Capital Public Equity Management, cutting an estimated $34.3M.

  • 132 institutional investors held PTC Therapeutics (PTCT) as of Q4 2014, up from 99 in Q3 2014.
  • Funds reported $1.47B of PTC Therapeutics stock for Q4 2014, up 37% quarter-over-quarter.
  • 38 funds opened new PTC Therapeutics positions in Q4 2014 and 5 closed out, a net change of +33 holders.
  • The largest PTC Therapeutics buyer in Q4 2014 was BB Biotech, an estimated $54.1M added.
  • The largest PTC Therapeutics seller in Q4 2014 was Bain Capital Public Equity Management, an estimated $34.3M sold.

Based on aggregated 13F filings for Q4 2014.